Abstract | OBJECTIVE: DATA SOURCES: DATA SYNTHESIS: Eight clinical trials and several observational studies were identified evaluating the safety and efficacy of ursodeoxycholic acid (UDCA) in the treatment of ICP. Although these studies were small and inconsistent, improvement in maternal and fetal morbidity was demonstrated. Observational studies suggest that cholestyramine may be associated with improved maternal morbidity without a documented improvement in fetal outcome. Two observational studies evaluated the efficacy of phenobarbital for ICP treatment. Phenobarbital use was not associated with improved maternal or fetal morbidity/mortality. CONCLUSIONS: Data from large, well-designed, randomized, controlled trials of treatment of ICP are lacking. Data that are available support the use of UDCA as a first-line agent and cholestyramine as a second-line agent for treatment of ICP. There is little evidence to recommend phenobarbital in the treatment of itching associated with that condition.
|
Authors | J Kimble Jenkins, Lisa A Boothby |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 36
Issue 9
Pg. 1462-5
(Sep 2002)
ISSN: 1060-0280 [Print] United States |
PMID | 12196068
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antipruritics
- Cholagogues and Choleretics
- Ursodeoxycholic Acid
- Phenobarbital
|
Topics |
- Adult
- Antipruritics
(therapeutic use)
- Cholagogues and Choleretics
(therapeutic use)
- Cholestasis, Intrahepatic
(complications, etiology)
- Female
- Humans
- Phenobarbital
(therapeutic use)
- Pregnancy
- Pregnancy Complications
(therapy)
- Pregnancy Outcome
- Prognosis
- Pruritus
(drug therapy, etiology)
- Ursodeoxycholic Acid
(therapeutic use)
|